title: A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.
abstract: The high cost and the long time required to bring drugs into commerce is driving efforts to repurpose FDA approved drugs-to find new uses for which they weren't intended, and to thereby reduce the overall cost of commercialization, and shorten the lag between drug discovery and availability. We report on the development, testing and application of a promising new approach to repositioning.
  
  
  
  Our approach is based on mining a human functional linkage network for inversely correlated modules of drug and disease gene targets. The method takes account of multiple information sources, including gene mutation, gene expression, and functional connectivity and proximity of within module genes.
  
  
  
  The method was used to identify candidates for treating breast and prostate cancer. We found that (i) the recall rate for FDA approved drugs for breast (prostate) cancer is 20/20 (10/11), while the rates for drugs in clinical trials were 131/154 and 82/106; (ii) the ROC/AUC performance substantially exceeds that of comparable methods; (iii) preliminary in vitro studies indicate that 5/5 candidates have therapeutic indices superior to that of Doxorubicin in MCF7 and SUM149 cancer cell lines. We briefly discuss the biological plausibility of the candidates at a molecular level in the context of the biological processes that they mediate.
  
  
  
  Our method appears to offer promise for the identification of multi-targeted drug candidates that can correct aberrant cellular functions. In particular the computational performance exceeded that of other CMap-based methods, and in vitro experiments indicate that 5/5 candidates have therapeutic indices superior to that of Doxorubicin in MCF7 and SUM149 cancer cell lines. The approach has the potential to provide a more efficient drug discovery pipeline.
authors.affiliation: Bioinformatics Program, College of Engineering, Boston University, Boston, MA, USA.|Graduate Program in Translational Molecular Medicine, Boston University School of Medicine, Boston, MA, USA.
authors.forename: Hsiao-Rong
authors.initials: HR
authors.lastname: Chen
authors.affiliation: Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA.
authors.forename: David H
authors.initials: DH
authors.lastname: Sherr
authors.affiliation: Bioinformatics Program, College of Engineering, Boston University, Boston, MA, USA.
authors.forename: Zhenjun
authors.initials: Z
authors.lastname: Hu
authors.affiliation: Bioinformatics Program, College of Engineering, Boston University, Boston, MA, USA. delisi@bu.edu.|Department of Biomedical Engineering, Boston University, Boston, MA, USA. delisi@bu.edu.
authors.forename: Charles
authors.initials: C
authors.lastname: DeLisi
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D019295:Computational Biology / Q000379:methods*; D057225:Data Mining; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D058492:Drug Repositioning / Q000379:methods*; D006801:Humans; D061986:MCF-7 Cells; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D004317:Doxorubicin
keywords: Cancer treatment; Computational drug repositioning; Drug screening